Evidence map›Paper›PMID 40928009›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Investment in Alzheimer's disease research for the next generation of adults with Down syndrome will yield health benefits for future generations.

Margaret M Weden, Lori Frank, Andrew W Dick, Zetianyu Wang, Susan Peschin, Diane E Bovenkamp, Sharyn L Rossi, Dana Sciullo, Hampus Hillerstrom, Richard A Fisher

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Margaret M WedenRAND Corporation, Santa Monica, California, USA.
Lori FrankNational Alliance for Caregiving, Washington, District of Columbia, USA.
Andrew W DickRAND Corporation, Santa Monica, California, USA.
Zetianyu WangRAND Corporation, Santa Monica, California, USA.
Susan PeschinAlliance for Aging Research, Washington, District of Columbia, USA.
Diane E BovenkampBrightFocus Foundation, Clarksburg, Maryland, USA.
Sharyn L RossiBrightFocus Foundation, Clarksburg, Maryland, USA.
Dana SciulloNational Down Syndrome Society, Washington, District of Columbia, USA.
Hampus HillerstromLuMind IDSC Foundation, Woburn, Massachusetts, USA.
Richard A FisherLuMind IDSC Foundation, Woburn, Massachusetts, USA.

Funding

Alliance for Aging ResearchBrightFocus® FoundationLuMind IDSC FoundationNational Down Syndrome Society
6 · The paper itself

Abstract

Recent innovations in Alzheimer's disease (AD) treatment highlight critical gaps in knowledge about how to support healthy aging of adults with Down syndrome (DS). RAND researchers updated demographic and epidemiological evidence about the DS population to assess the impact of increased investment in treatment innovations for DS-associated Alzheimer's disease (DS-AD). They estimated life expectancy at birth in 2020 to be 55 years, with ≈ 5 years of DS-AD. They found that the results of investment were dramatic. Between 2020 and 2070, adult years of life are expected to increase by 5 years without any increase in unhealthy years of life with DS-AD. Caregiving hours for individuals with DS-AD are expected to be reduced by 40%, which will generate large annual savings. The new evidence underscores the magnitude of the impact that investment in DS-AD treatments could have for individuals with DS, their families, and caregivers. HIGHLIGHTS: Evidence is sparse about treatment for Down syndrome (DS)-associated Alzheimer's disease (DS-AD) and healthy aging of DS adults. This population simulation model estimates DS-AD caregiving costs at ≈ $1 billion per year. DS-AD innovations could increase life expectancy by 5 years and reduce caregiving by 40% by 2070. This better forecasting can improve policy and service planning. DS-AD research investment could yield dramatic gains for individuals and families.

Indexed as

Alzheimer DiseaseBiomedical ResearchDown SyndromeAdultCaregiversHumansLife ExpectancyagingAlzheimer's diseasedevelopmental disabilitiesDown syndromeethicshealth servicesneuroscience/neurology

Identifiers

PMID40928009
PMCPMC12421411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.